Abstract
Favipiravir, an antiviral agent, is undergoing clinical trials for treating novel coronavirus disease 2019 (COVID-19). Here, we report two cases of COVID-19 with favipiravir-induced fever. In both cases, pyrexia was observed following the administration of favipiravir despite improvements in symptoms of COVID-19. No other cause for fever was evident after careful physical examination and laboratory investigation. The fever subsided in both patients after the discontinuation of favipiravir. To the best of our knowledge, this is the first report of favipiravir-induced fever in COVID-19 patients.
Keywords: COVID-19; Drug fever; Favipiravir.
All Keywords
【저자키워드】 COVID-19, Favipiravir, drug fever, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, clinical trial, Antiviral, knowledge, Favipiravir, clinical trials, drug, novel coronavirus disease, drug fever, Novel coronavirus, improvement, Physical examination, Fever, Patient, antiviral agent, COVID-19 patients, administration, best, Improvements, symptoms of COVID-19, Pyrexia, laboratory investigation, 【제목키워드】 Fever,
【저자키워드】 COVID-19, Favipiravir, drug fever, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, clinical trial, Antiviral, knowledge, Favipiravir, clinical trials, drug, novel coronavirus disease, drug fever, Novel coronavirus, improvement, Physical examination, Fever, Patient, antiviral agent, COVID-19 patients, administration, best, Improvements, symptoms of COVID-19, Pyrexia, laboratory investigation, 【제목키워드】 Fever,
{{{ 추상적인 }}}
항바이러스제 파비피라비르(Favipiravir)가 신종 코로나바이러스 감염증(코로나19) 2019(COVID-19) 치료제 임상시험을 진행하고 있다. 여기에서는 파비피라비르에 의해 유발된 발열을 동반한 2건의 COVID-19 사례를 보고합니다. 두 경우 모두 코로나19의 증상이 개선되었음에도 불구하고 파비피라비르 투여 후 발열이 관찰되었습니다. 주의 깊은 신체 검사와 실험실 조사 후에 발열의 다른 원인은 분명하지 않았습니다. favipiravir 중단 후 두 환자 모두에서 열이 가라앉았다. 우리가 아는 한, 이것은 COVID-19 환자에서 favipiravir에 의한 열에 대한 첫 번째 보고서입니다.
{{ 키워드: }} 코로나19; 마약 열; 파비피라비르.